In the CASPIAN trial, PD-L1 positivity was observed in approximately 5.7% of tumor cells and 25.8% of immune cells (28.3% in either), and durvalumab plus chemotherapy improved survival regardless of PD-L1 status (11). Here, CD274 is linked to neoplasm.